Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488279 · ClinicalTrials.gov registry record · NA
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01488279: Completed NA study, sponsored by University of Vermont.
NCT01488279 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488279, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Primary Outcome
Insulin Sensitivity measured at the end of each treatment period. The primary outcome variable was the difference in the disposition index (DI) determined as the product of the acute insulin response to glucose (AIRg) x the insulin sensitivity index (SI) in subjects during IVGTT on the 8th day (after 7 days) of on dex + placebo, then a after a washout of approximately 4 weeks, participants crossed over to dex + sitagliptin 100 mg x 7 days. Subjects were randomized to order of medication. The pri
Interventions
- DRUG Dexamethasone 2.5 mg and Sitagliptin 100 mg
- DRUG Dexamethasone 2.5 mg and placebo tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT01488279 record still lists
NCT01488279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone 2.5 mg and Sitagliptin 100 mg is the first listed.
NCT01488279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01488279 about?
NCT01488279 is a clinical study titled "Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy". The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
What is the current status of trial NCT01488279?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2012-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01488279?
The interventions under investigation include: Dexamethasone 2.5 mg and Sitagliptin 100 mg (DRUG), Dexamethasone 2.5 mg and placebo tablet (DRUG).
Who is sponsoring clinical trial NCT01488279?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01488279's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia